LXLing Xu

Ling Xu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ling Xu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Junping Zhang

    First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine, Tianjin, China

    1 shared publication
  • Meifang Wu

    The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

    1 shared publication
  • Meng Li

    School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China

    1 shared publication
  • Qiang Wang

    The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China

    1 shared publication
  • Shichao Lv

    Department of Geriatrics, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine, No 88 Changling Road, Tianjin, 300381, China, 86 13920127740

    1 shared publication
  • Xiao-Jing Wang

    Institute of Materia Medica, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan 250000, China

    1 shared publication

Latest Publications

  • Open Access

    QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats

    by Shichao Lv, Qiang Wang, Meifang Wu, Meng Li, Xiaojing Wang, Ling Xu, Junping Zhang

    Pressure-overloaded myocardial hypertrophy is an independent risk factor for various cardiovascular diseases (CVDs), such as heart failure (HF), arrhythmia, and even sudden death. It is reported that QiShenYiQi pill (QSYQ) is widely used in the treatment of CVDs and can prevent pathological hypertrophy of myocardium, but its specific mechanism is still unclear. In this study, a rat model of myocardial hypertrophy was established through the pressure overload caused by abdominal aortic constriction in Wistar rats. The rats were randomly divided into model group, valsartan group, and QSYQ group, and sham-operated animals served as the control group. At the 4 and 8 weeks of intervention, the general morphology of the heart, myocardial collagen content, collagen volume factor (CVF), collagen type I, collagen type III, myocardial pathological changes, and the expression of ANP, β-MHC, TGF-β1, and CTGF were analyzed, respectively, in order to explore the possible effect of QSYQ on the mechanism of myocardial hypertrophy. We observed that QSYQ could effectively improve myocardial hypertrophy in pressure-overloaded rats, which was related to the regulatory mechanism of TGF-β1 and CTGF.